Login to Your Account

Ionis/Akcea tie $1.6B knot; CV bid with Novartis adds to better spin on Spinraza

By Randy Osborne
Staff Writer

Thursday, February 16, 2017

With a pair of drugs devoted to what Ionis Pharmaceuticals Inc. CEO Stanley Crooke called "systematically knocking off the remaining lipid risk factors" for patients facing CV trouble, the company closed a potential $1.6 billion deal with Novartis AG.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription